APA (7th ed.) Citation

Antonia, S. J., & Jäger, D. (2016). Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. The lancet. Oncology, 17(7), . https://doi.org/10.1016/S1470-2045(16)30098-5

Chicago Style (17th ed.) Citation

Antonia, Scott J., and Dirk Jäger. "Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-cell Lung Cancer (CheckMate 032): A Multicentre, Open-label, Phase 1/2 Trial." The Lancet. Oncology 17, no. 7 (2016). https://doi.org/10.1016/S1470-2045(16)30098-5.

MLA (9th ed.) Citation

Antonia, Scott J., and Dirk Jäger. "Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-cell Lung Cancer (CheckMate 032): A Multicentre, Open-label, Phase 1/2 Trial." The Lancet. Oncology, vol. 17, no. 7, 2016, https://doi.org/10.1016/S1470-2045(16)30098-5.